Adherus®

AutoSpray Dural Sealant

The first dual indicated dural sealant





Adherus® AutoSpray

One product, two indications

Adherus AutoSpray Dural Sealant is indicated for use in patients who are 13 years of age and older, as an adjunct to standard methods of dural repair, such as sutures, to provide watertight closure during cranial and spinal procedures.



Polyethylene glycol (PEG)
Pre-assembled applicator

Polyethyleneimine (PEI)
Pre-assembled applicator

1 Second set time
The Adherus hydrogel sets in approximately one second. It remains where it is applied.[4]

1 Minute setup
Easy setup. Ready to use in one minute.

17 Crosslinks
Adherus AutoSpray Dural Sealant has been designed with an average of 17 crosslinking endpoints to help increase strength and minimize swelling.

0 Infections
Among the subjects treated with Adherus AutoSpray Dural Sealant in two pivotal randomized controlled trials, there were no device related infections and no cases of meningitis.[3,6]

Comparing swelling[4, 6]

Over 40 days, DuraSeal shows up to 66% swelling, DuraSeal Exact shows up to 56% swelling and Adherus shows up to 17% swelling.[4,6]



Comparing burst strength[4, 6]

Max ICP is 47 cm H_20[5]. Adherus maintains its burst strength for an extended period of time.



Spinal Indication Clinical Trial[6]

The Adherus spinal indication clinical trial was a large scale, prospective randomized, single blind, non-inferiority, clinical trial.

- 14 sites, 94 patients (50 Adherus and 44 DuraSeal Exact), 90-day follow-up.
- Adherus was 96.5 % free from CSF leak or pseudomeningocele after 90 days compared to DuraSeal Exact at 91.1%.
- There were no AEs due to device deficiencies/malfunctions or unanticipated Adverse Device Effects in the study.
- No cases of meningitis or deep surgical site infection were observed during 90-day follow-up of patients treated with Adherus.

Craniomaxillofacial

Contraindications: Adherus AutoSpray Dural Sealant should not be used in confined anatomical spaces where nerve compression is of concern. The hydrogel may swell by up to 13% of its size in any dimension of 46% by volume after application.

This document is intended solely for the use of healthcare professionals. A surgeon must always rely on his or her own professional clinical judgment when deciding whether to use a particular product when treating a particular patient. Stryker does not dispense medical advice and recommends that surgeons be trained in the use of any particular product before using it in surgery.
The information presented is intended to demonstrate a Stryker product. A surgeon must always refer to the package insert, product label and/or instructions for use, including the instructions for cleaning and sterilization (inapplicable), before using any Stryker product. Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your Stryker representative if you have questions about the availability of Stryker products in your area. Stryker Corporation or its divisions or other corporate affiliated entities own, use or have applied for the following trademarks or service marks: Adherus, Stryker. All other trademarks are trademarks of their respective owners or holders.
Adherus and Adherus ET are the only FDA-approved hydrogel dural sealant with a patent pending AutoSpray applicator with internal air pump.

References:

1: van Doormaal T, Kinaci A, van Thoor S, et al. Usefulness of Sealants for Dural Closure: Evaluation in an In Vitro Model. Operative Neurosurgery. 15(4): 425-432;2018.
2: Data on file with Stryker
3: Tew, Jr JM, Strong MJ, West GA, Woo H, Couture DE, Wilson JA, Munoz LF, Rosen CL, Greenlee JD, van Loveren HR, Iantosca M, Baird CJ, Smith M, McGirt M, Parish J, Asher AL. A Pivotal Randomized Clinical Trial Evaluating the Safety and Effectiveness of a Novel Hydrogel Dural Sealant as an Adjunct to Dural Repair.Oper Neurosurg13:204-212, 2017.Distributed by: Stryker Craniomaxillofacial Kalamazoo, MI 49002 USA: 269 389 5346toll free: 800 962 6558f: 877 648 7114
4: Strong MJ, Carnahan MA, D'Alessio K, Butlin JDG, Butt MT, Asher AL. Preclinical characterization and safety of a novel hydrogel for augmenting dural repair. Mater.
Res. Express. 2:095401, 2015.
5. POSB78 Economic Analysis of Adherus AutoSpray Dural Sealant As an Adjunct to Standard Methods of Dural Repair to Provide Watertight Closure during Cranial
Procedures: Postoperative Complications and Costs. Meinert I, et al. Value in Health. Volume 25, Issue 1, S75.
6: D0000442612 DuraSeal Benchmarking Analysis - Data on file

Manufactured by:
HyperBranch Medical Technology, Inc., a subsidiary of Stryker, located in Durham, North Carolina USA. All rights reserved.
Distributed by:
Stryker Craniomaxillofacial
Kalamazoo, MI 49002 USA
T: 269 389 5346
Copyright @ Stryker 2026